Significant Friday Options Trading: HROW, EWTX, RBLX
EWTX Options Activity: Edgewise Therapeutics Inc (EWTX) has seen a trading volume of 6,697 options contracts today, equating to about 669,700 underlying shares, which is 55.2% of its average daily trading volume over the past month.
High Volume Call Option for EWTX: The $24 strike call option expiring on December 19, 2025, has particularly high activity with 3,385 contracts traded, representing approximately 338,500 underlying shares.
RBLX Options Activity: Roblox Corp (RBLX) has recorded a trading volume of 40,105 options contracts today, amounting to around 4.0 million underlying shares, which is 54.3% of its average daily trading volume over the past month.
High Volume Call Option for RBLX: The $105 strike call option expiring on January 16, 2026, has seen significant trading with 5,351 contracts, representing about 535,100 underlying shares.
Trade with 70% Backtested Accuracy
Analyst Views on EWTX
About EWTX
About the author

iShares U.S. Pharmaceuticals ETF Declines 1.8% on Thursday
- ETF Underperformance: The iShares U.S. Pharmaceuticals ETF fell approximately 1.8% during Thursday afternoon trading, indicating a weak performance that may undermine investor confidence.
- Weak Component Stocks: Among the ETF's weakest performers were Omeros, down about 7%, and Edgewise Therapeutics, down approximately 6.4%, highlighting the overall pressure within the pharmaceutical sector.
- Market Volatility Impact: The overall market volatility on Thursday may have exacerbated investor concerns regarding the pharmaceutical industry, leading to capital outflows that further impacted the ETF's performance.
- Investor Sentiment Shift: As pharmaceutical stocks decline, investors may reassess their investment strategies in the sector, potentially influencing future capital flows and market dynamics.

Edgewise Therapeutics CEO to Present at 44th J.P. Morgan Healthcare Conference
- Conference Presentation: Edgewise Therapeutics CEO Kevin Koch, Ph.D., will present at the 44th J.P. Morgan Healthcare Conference on January 13, 2026, where he is expected to discuss the company's latest advancements in muscle disease treatments, enhancing its visibility in the biopharmaceutical industry.
- Live Webcast: The presentation will be webcast live, allowing users to connect a few minutes prior to ensure timely access, which not only facilitates information dissemination to investors but also strengthens the company's engagement with its stakeholders.
- Product Development: Edgewise is developing Sevasemten, a first-in-class orally administered fast skeletal myosin inhibitor currently in late-stage clinical trials for Becker and Duchenne muscular dystrophies, showcasing the company's innovative potential in muscle disease therapies.
- Cardiac Disease Treatments: The company is also advancing EDG-7500 and EDG-15400 in clinical development for hypertrophic cardiomyopathy and heart failure, respectively, indicating Edgewise's strategic positioning in the cardiac treatment market to meet growing demand.






